Annovis Bio (ANVS) Interest & Investment Income (2023 - 2026)
Annovis Bio (ANVS) posted Interest & Investment Income of $137800.0 for Q1 2026, down 17.85% sequentially from $167737.0 in Q4 2025, and down 26.55% YoY from $187612.0 in Q1 2025.
Annovis Bio (ANVS) Interest & Investment Income (2023 - 2026) Analysis & Trends
Annovis Bio has reported Interest & Investment Income for 4 years, with the latest figure at $137800.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 26.55% year-over-year to $137800.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $649249.0 (up 36.6% YoY) and the FY2025 annual result came in at $699061.0, up 110.66% from the prior year.
- Interest & Investment Income fell to $137800.0 in Q1 2026 per ANVS's latest filing, from $167737.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $191395.0 in Q2 2025 and troughed at $25978.0 in Q2 2024.
- A 4-year average of $125590.5 and a median of $137800.0 in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2025 and 2026: Interest & Investment Income jumped 636.76% in 2025, then retreated 26.55% in 2026.
- Over 4 years, Interest & Investment Income stood at $66130.0 in 2023, then surged by 90.95% to $126273.0 in 2024, then soared by 32.84% to $167737.0 in 2025, then decreased by 17.85% to $137800.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $137800.0, $167737.0, and $152317.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | 160,233.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 137,800.00 |
| Dec 31, 2025 | 167,737.00 |
| Sep 30, 2025 | 152,317.00 |
| Jun 30, 2025 | 191,395.00 |
| Mar 31, 2025 | 187,612.00 |
| Dec 31, 2024 | 126,273.00 |
| Sep 30, 2024 | 135,430.00 |
| Jun 30, 2024 | 25,978.00 |
| Mar 31, 2024 | 44,168.00 |
| Dec 31, 2023 | 66,130.00 |
| Sep 30, 2023 | 146,655.00 |